Abstract Number: 1713 • ACR Convergence 2023
Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…Abstract Number: 1736 • ACR Convergence 2023
The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis
Background/Purpose: Osteoclasts (OCs) are multinucleated bone-resorbing cells playing a key role in rheumatoid arthritis (RA). Under physiological conditions, OCs are in balance with bone-forming osteoblasts,…Abstract Number: 1752 • ACR Convergence 2023
Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint
Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed…Abstract Number: 1768 • ACR Convergence 2023
The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…Abstract Number: 1867 • ACR Convergence 2023
Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…Abstract Number: 2021 • ACR Convergence 2023
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…Abstract Number: 2106 • ACR Convergence 2023
Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients…Abstract Number: 2122 • ACR Convergence 2023
Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study
Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…Abstract Number: 2138 • ACR Convergence 2023
Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis
Background/Purpose: Frailty occurs prematurely in RA. Levels of frailty are higher in Veteran populations than civilians1. Frailty has been shown to predict osteoporotic fractures in…Abstract Number: 2154 • ACR Convergence 2023
Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…Abstract Number: 2171 • ACR Convergence 2023
Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?
Background/Purpose: To date, there are no head-to-head clinical trials directly comparing the effects between IL-6i and JAKi on bone destruction in RA. In recent years,…Abstract Number: 2451 • ACR Convergence 2023
TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank
Background/Purpose: Clonal hematopoiesis (CH), the clonal expansion of somatically mutated blood cells in people without hematologic malignancy, is found in ~10% of people age ≥…Abstract Number: 2541 • ACR Convergence 2023
Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…Abstract Number: 0029 • ACR Convergence 2023
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts
Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease…Abstract Number: 0094 • ACR Convergence 2023
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 188
- Next Page »